A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis.
A controlled clinical study employing a double-blind, double-dummy technique was carried out on 84 patients with purulent exacerbations of chronic bronchitis. Ofloxacin (200 mg x 2 daily) and pivampicillin (700 mg x 3 daily), were compared for efficacy, safety, and adverse reactions. Both regimens had high bacteriological elimination rates (94.1, 97.2%) and clinical cure rates (97.4, 97.6%). However, there were fewer adverse reactions and a greater patient acceptance in the ofloxacin treated group.
Egede
F
F
Department of Chest Medicine, University Hospital, Odense S. Denmark.
Kristensen
I
I
D000208:Acute Disease; D000667:Ampicillin / Q000031:analogs & derivatives*; D001991:Bronchitis / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D010917:Pivampicillin / Q000009:adverse effects / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology
D010917:Pivampicillin; D000667:Ampicillin; D015242:Ofloxacin